15-78590583-G-A
Variant summary
Our verdict is Benign. Variant got -12 ACMG points: 0P and 12B. BP4_StrongBA1
The ENST00000299565.9(CHRNA5):c.1192G>A(p.Asp398Asn) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.302 in 1,613,800 control chromosomes in the GnomAD database, including 79,728 homozygotes. In-silico tool predicts a benign outcome for this variant. 12/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as drug response (★★★).
Frequency
Consequence
ENST00000299565.9 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -12 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CHRNA5 | NM_000745.4 | c.1192G>A | p.Asp398Asn | missense_variant | 5/6 | ENST00000299565.9 | NP_000736.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CHRNA5 | ENST00000299565.9 | c.1192G>A | p.Asp398Asn | missense_variant | 5/6 | 1 | NM_000745.4 | ENSP00000299565 | P1 | |
ENST00000567141.1 | n.694C>T | non_coding_transcript_exon_variant | 1/1 |
Frequencies
GnomAD3 genomes AF: 0.240 AC: 36562AN: 152040Hom.: 5789 Cov.: 32
GnomAD3 exomes AF: 0.264 AC: 66316AN: 250966Hom.: 10589 AF XY: 0.276 AC XY: 37394AN XY: 135724
GnomAD4 exome AF: 0.308 AC: 450162AN: 1461642Hom.: 73939 Cov.: 38 AF XY: 0.308 AC XY: 223838AN XY: 727150
GnomAD4 genome AF: 0.240 AC: 36562AN: 152158Hom.: 5789 Cov.: 32 AF XY: 0.238 AC XY: 17675AN XY: 74388
ClinVar
Submissions by phenotype
Susceptibility to severe coronavirus disease (COVID-19) due to high levels of fibrinogen and C-reactive protein Uncertain:1
Uncertain significance, no assertion criteria provided | research | HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas | - | - - |
Lung cancer susceptibility 2 Other:1
risk factor, no assertion criteria provided | literature only | OMIM | Jul 27, 2010 | - - |
nicotine response - Toxicity Other:1
drug response, reviewed by expert panel | curation | PharmGKB | Mar 24, 2021 | PharmGKB Level of Evidence 2B: Variants in Level 2B clinical annotations are not in PharmGKB’s Tier 1 VIPs. These clinical annotations describe variant-drug combinations with a moderate level of evidence supporting the association. For example, the association may be found in multiple cohorts, but there may be a minority of studies that do not support the majority assertion. Level 2B clinical annotations must be supported by at least two independent publications. Drug-variant association: Toxicity |
Smoking as a quantitative trait locus 3 Other:1
risk factor, no assertion criteria provided | literature only | OMIM | Jul 27, 2010 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at